Epi Auto Injector denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for epi auto injector are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why This Denial Is Almost Certainly Incorrect — and Urgently Appealable

Epinephrine auto-injectors are the established, FDA-approved standard of care for emergency treatment of anaphylaxis. They are explicitly recommended by every major allergy, immunology, and emergency medicine professional society. A BlueCross BlueShield denial categorizing an epinephrine auto-injector as "experimental" or "investigational" represents either an administrative coding error or a significant utilization-management mistake. This denial category is reserved for drugs or devices that lack FDA approval or adequate clinical evidence — neither of which applies to epinephrine.

Because epinephrine auto-injectors are emergency medications for a potentially life-threatening condition, this denial should be treated as urgent and appealed immediately.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): You have the right to a full written explanation of the specific basis on which BCBS classified this device as experimental. Request the exact clinical criteria or technology assessment used.
• External review (ACA §2719): After internal appeals, you may request binding independent external review from an accredited IRO. An IRO will almost certainly find that epinephrine auto-injectors meet generally accepted standards of medical care.
• Expedited review — strongly recommended here: Because anaphylaxis is a potentially life-threatening emergency, request expedited internal review (plan must respond within 72 hours) and expedited external review (IRO must respond within 72 hours) simultaneously if legally permitted in your state.
• Four-month window: External review requests are typically due within approximately four months of the final internal denial — but do not wait; file promptly given the emergency nature of this medication.

## The Concrete Appeal Process

1. Request the written denial rationale and the specific BCBS technology assessment or clinical policy used to classify the device as experimental. 2. Obtain the FDA approval documentation for the specific epinephrine auto-injector prescribed (available on FDA.gov). 3. Identify the professional society guidelines (American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; or equivalent) that endorse epinephrine auto-injectors as standard of care. 4. Have your prescriber write a medical-necessity letter. 5. Submit all materials together in a formal expedited internal appeal, citing both the FDA approval and accepted clinical guidelines. 6. If not immediately reversed, proceed to expedited external review.

## Documentation to Gather

• FDA approval documentation: The current FDA-approved labeling for the specific auto-injector device, confirming it is approved for emergency epinephrine administration.
• Anaphylaxis diagnosis records: Physician documentation of the patient's anaphylaxis risk, triggering allergen(s), and clinical history supporting the prescription.
• Professional society guideline references: Citations (organization and title, not specific numerical thresholds) confirming epinephrine auto-injectors are the accepted standard of care for anaphylaxis.
• Prescriber letter: A letter from the allergist or treating physician explaining the diagnosis, the standard-of-care basis for prescribing, and the life-threatening nature of anaphylaxis if the medication is unavailable.

## Criteria-Mapping Strategy

The experimental-denial criterion requires the plan to show the drug or device lacks adequate clinical evidence or FDA approval. Your appeal dismantles this on both grounds: FDA approval is documented fact, and every major relevant professional society endorses this device. Present the evidence in a brief, factual cover letter accompanied by the FDA label. This is the strongest possible appeal posture for this denial type.